Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 20/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | PTAFR | P25105 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16522203 | 0.96 | TACR1 (0.65) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL17932890 | 0.94 | TACR1 (0.61) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL17924507 | 0.94 | TACR1 (0.61) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL16515759 | 0.94 | TACR1 (0.53) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL16522277 | 0.94 | TACR1 (0.53) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL17233168 | 0.91 | TACR1 (0.50) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL17924546 | 0.91 | TACR1 (0.58) | TACR1SIGMAR1PTAFR | |
| SCHEMBL17924379 | 0.91 | TACR1 (0.58) | TACR1SIGMAR1PTAFR | |
| SCHEMBL16522140 | 0.90 | TACR1 (0.56) | TACR1SIGMAR1PTAFRCYP3A4 | |
| SCHEMBL16515811 | 0.90 | TACR1 (0.56) | TACR1SIGMAR1PTAFRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3036236-B1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA AS (DK) | 2017-06-07 | — | — | EP | claimed |
| EP-3036236-B1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| EP-3036236-B1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA AS (DK) | 2017-06-07 | — | — | EP | disclosed |
| US-20160207930-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-20160207930-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA A/S (DK) | 2016-07-21 | — | — | US | disclosed |
| US-20160207930-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | LEO PHARMA A/S (DK) | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160207930-A1 | NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS II | TACR2, TACR1, HRH4 | TACR1 2/4885SIGMAR1 42/4885PTAFR 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.